Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Prostate cancer: Multiparametric MRI strategy misses clinically significant cancer
Key clinical point: In biopsy-naive men, multiparametric magnetic resonance imaging (mpMRI) and contrast ultrasound dispersion imaging (CUDI) strategies have inferior detection rates for clinically significant (grade group [GG] ≥2) prostate cancer vs. systematic biopsy.
Major finding: Systematic biopsy vs. mpMRI and CUDI detected significantly more GG ≥2 cancer (39% vs. 29% and 28%; P less than .05) and GG = 1 cancer (14% vs. 1% and 3%; P less than .05).
Study details: Interim analysis of a prospective, single-center trial included 142 biopsy-naive men who underwent prebiopsy mpMRI or CUDI followed by a 12-core systematic biopsy.
Disclosures: This study was funded by the Dutch Cancer Society. The authors declared no conflicts of interest.
Mannaerts CK et al. BJU Int. 2020 Apr 21. doi: 10.1111/bju.15093.